Exclusive Online Content
PDC* line Pharma Opens Last Cohort of PDC-Lung-101 Clinical Trial
PDC*line Pharma recently announced the last cohort of patients has been opened and the first patients were dosed, in the PDC-LUNG-101 Phase 1/2 clinical trial (NCT03970746) with PDC*lung01, the company’s therapeutic cancer….
ESCP Models - Hepatitis C Medications (Part 2), Oral Therapeutics
Part 2 of this series fills in the story starting with the first oral HCV therapeutic, Vertex’s Incivek (telaprevir), which predated the first of the Gilead therapeutics by 2.5 years…
Stingthera Announces Clinical Collaboration With Merck to Evaluate SNX281 in Combination With KEYTRUDA in Certain Patients With Advanced Solid Tumors & Lymphoma
Stingthera, Inc. recently announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the combination of SNX281, Stingthera’s investigational….
Dunad Therapeutics Enters Strategic Collaboration With Novartis to Develop Next-Generation Oral Targeted Protein Degrader Therapies
Dunad Therapeutics recently announced it has entered a strategic collaboration and license agreement with Novartis to generate orally bioavailable covalent and protein degrading small molecule drugs…..
Coherus & Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. recently announced the US FDA has accepted for review the Biologics License Application (BLA) for toripalimab in combination with….
Gattefossé Expands its Offer With the Launch of Three New Pharmaceutical Excipients
Gattefossé, supplier of specialty ingredients for the health and beauty industries, announces the launch of three new pharmaceutical ingredients: Labrafac™ MC60 and Gelucire® 59/14, for the for oral administration route and Emulfree® Duo….
Nemera Launches UniSpray, its Unidose System Primarily for Systemic-Acting Drug Administration
Nemera has a proven track record in developing and manufacturing complex Ear Nose and Throat solutions. In line with clear growing market interest in unidose system coupled with promising advantages that nasal route could….
Ocugen, Inc. Announces Submission of IND to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate
Ocugen, Inc. recently announced that it has submitted an Investigational New Drug application (IND) with the US FDA to evaluate the COVID-19 vaccine….
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. recently announced the completion of enrollment in the company’s ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy….
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy & Powerful Potential of Antigen-Independent Tumor Targeting
Cybrexa Therapeutics recently announced favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex-exatecan). The initial data show robust….
Berkeley Lights Announces GSK Acquires Third Beacon Optofluidic System to Expand Antibody Therapeutics Development
Berkeley Lights, Inc. recently announced GlaxoSmithKline (GSK) has purchased an additional Beacon Optofluidic system to expand its antibody therapeutics capacity. The new Beacon system will….
Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever System in Pulmonary Embolism Patients
Inari Medical, Inc. recently announced planned enrollment of the PEERLESS trial. PEERLESS is a new randomized controlled trial (RCT) comparing the clinical outcomes of patients with intermediate-high risk pulmonary embolism….
Quris Closes Critical Drug Development Gaps With New Clinical Prediction AI Platform
Quris recently launched the first clinical prediction AI platform to predict which drug candidates will safely work in humans – significantly improving efficacy and cutting drug development….
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
Phathom Pharmaceuticals, Inc. recently announced that vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, a pivotal Phase 3 trial evaluating….
Menarini Group & Radius Health Announce Positive Phase 3 Topline Results From the EMERALD Trial Evaluating Elacestrant in Breast Cancer
The Menarini Group and Radius Health, Inc. recently announced positive topline results from the EMERALD study. The study was designed to evaluate elacestrant as a….
Credence MedSystems Announces Strategic Collaboration With Phillips Medisize
Credence MedSystems, Inc. recently announced it has formed a strategic collaboration with Phillips-Medisize, a Molex company, a global leader in the design and manufacturing of solutions for the pharmaceutical drug delivery market…..
Ascendia Once Again Ranked on Inc. 5000 List of America’s Fastest-Growing Private Companies
Inc. magazine revealed that Ascendia Pharmaceuticals rose 3,239 positions on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies…..
BD Launches Plunger Stopper in Partnership With Aptar Pharma to Enhance Biologic Drug Delivery
BD (Becton, Dickinson and Company) recently announced the launch of the BD SCF PremiumCoat Plunger Stopper in partnership with Aptar Pharma, a global leader in drug delivery solutions and services…..
PCI Pharma Services Announces the Acquisition of LSNE to Add End-to-End Global Sterile Fill-Finish & Lyophilization Manufacturing Capabilities
PCI Pharma Services (PCI) recently announced it has signed a definitive agreement to acquire Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization (CDMO)….
Pace Life Sciences Acquires Velesco Pharmaceutical Services, Expanding Capabilities in Drug Development Services
Pace Analytical Life Sciences, LLC, a subsidiary of Pace Analytical Services, LLC, a full-service contract development and manufacturing organization (CDMO), recently announced that it has acquired Velesco….
